{"id":4482,"date":"2020-08-27T23:46:22","date_gmt":"2020-08-27T22:46:22","guid":{"rendered":"https:\/\/thedailyleaks.com\/?p=4482"},"modified":"2020-08-27T23:46:22","modified_gmt":"2020-08-27T22:46:22","slug":"trump-administration-to-purchase-150-million-rapid-covid-19-tests","status":"publish","type":"post","link":"https:\/\/thedailyleaks.com\/trump-administration-to-purchase-150-million-rapid-covid-19-tests\/","title":{"rendered":"Trump administration to purchase 150 million rapid COVID-19 tests"},"content":{"rendered":"

\"Trump\u00a9 Getty Images<\/p>\n

\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n

The Trump administration plans to purchase nearly all of the new rapid COVID-19 tests that Abbott Labs will manufacture this year, a White House official confirmed.<\/p>\n

The administration will purchase 150 million tests as part of the $750 million deal, which\u00a0President Trump<\/a><\/span>\u00a0is expected to announce later\u00a0Thursday during his speech\u00a0to accept the\u00a0GOP presidential nomination during the\u00a0Republican National Convention.<\/p>\n

The plan was first\u00a0reported by Politico.<\/a><\/p>\n

Abbott’s BinaxNOW is a potentially breakthrough new tool that can deliver results in 15 minutes. It is entirely self-contained, meaning there is no extra lab equipment needed to run the test, and large volumes of tests can be performed simultaneously.<\/p>\n

The Food and Drug Administration (FDA) granted Abbott an emergency use authorization for the tests Wednesday.<\/p>\n

The Hill<\/a> said the company plans to begin shipping them by the end of the month, with “tens of millions” of tests in September, and 50 million tests a month by the beginning of October.<\/p>\n

\u201cThis is a major development that will help our country to remain open, get Americans back to work, and kids back to school,\u201d White House strategic communications director Alyssa Farah said in a statement. \u201cThe Trump Administration is proud to partner with Abbott labs to make this purchase possible to help the American people.\u201d<\/p>\n

The move would represent a significant expansion of the current U.S. testing capabilities, which have often not been able to keep up with demand.<\/p>\n

The administration did not say where the tests will be sent once they are purchased.<\/p>\n

The test uses a nasal swab and a small reactive card. Under the FDA’s emergency authorization, it can be administered at\u00a0patient care facilities by a range of health care workers, including physicians, school nurses and pharmacists with minimal training.<\/p>\n

ALSO READ:<\/strong><\/p>\n

\n
\n